Kezar Life Sciences, Inc.
KZRKezar Life Sciences, Inc.
We are a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. In October 2025, we announced plans to explore strategic alternatives focused on maximizing stockholder value after being unable to align with the U.S.
ROIC dropped from -42.15% to -45.45%, capital efficiency is deteriorating. Negative free cash flow of -$52M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
Net Income (TTM)
-$45M
▲ +33.1% YoY
Op. Margin
—
ROIC
-45.97%
▼ -3.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$42M
▲ +30.2% YoY
Op. Cash Flow (TTM)
-$42M
▲ +30.2% YoY
Net Debt
-$65M
Net Cash Position
Cash & Equiv.
$66M
Continue Research
SourceComputed from the 10-Q filed 7 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 6 Oct 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.